Related Experiment Videos
Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review
Patrick Roland Boulos1, Isabelle Hardy
1Department of Ophthalmic Plastics and Reconstructive Surgery, University of Montreal Medical School, Montreal, Quebec, Canada.
Current Opinion in Ophthalmology
|January 1, 2005
Summary
Recent advancements in thyroid-associated orbitopathy (TAO) offer more targeted treatments. Understanding TAO pathophysiology guides diagnosis and therapy, moving towards less invasive interventions with reduced patient morbidity.
Area of Science:
- Ophthalmology
- Endocrinology
- Immunology
Background:
- Thyroid-associated orbitopathy (TAO) is an autoimmune condition affecting the eye socket.
- Recent research highlights the role of fibroblasts and adipogenesis in TAO pathogenesis.
- Thyroid stimulating hormone receptor expression is significant in orbital tissues.
Purpose of the Study:
- To review current literature on thyroid-associated orbitopathy.
- To highlight recent developments in TAO pathophysiology, diagnosis, and treatment.
- To discuss current therapeutic trends and controversies in managing TAO.
Main Methods:
- Literature review of recent studies on thyroid-associated orbitopathy.
- Analysis of diagnostic advancements, including electrophysiology and scintigraphy.
- Evaluation of evolving therapeutic strategies for TAO management.
Main Results:
- Thyroid stimulating hormone receptor is highly expressed in orbital fat and connective tissue, with fibroblasts showing adipogenic potential.
- Subclinical optic neuropathy is detectable via electrophysiology; somatostatin-receptor scintigraphy aids in justifying immunomodulation.
- Therapeutic options include steroids, controversial radiotherapy for inflammation, and surgical decompression techniques (fat removal, implants) for proptosis reduction (0.9-12.5mm).
- Botulinum toxin and blepharotomy are used for strabismus, intraocular pressure, and eyelid retraction.
Conclusions:
- Growing understanding of TAO pathophysiology is driving a shift towards more targeted, less invasive treatments.
- Modern approaches aim to reduce morbidity associated with managing thyroid-associated orbitopathy.
- Future treatments will likely be more precise and personalized based on disease mechanisms.